期刊文献+

抗核抗体和抗环瓜氨酸肽抗体在风湿性疾病中的应用 被引量:3

Application of ANA and anti-CCP antibody in rheumatic diseases
下载PDF
导出
摘要 目的探讨抗核抗体(ANA)和抗环瓜氨酸肽(CCP)抗体在风湿性疾病中的敏感性及相关性。方法收集浏阳市人民医院2010年9月至2013年2月433例已确诊为风湿性疾病患者和60例健康体检人员的血清,采用间接免疫荧光试验(IIFA)检测ANA,判断荧光核型,免疫印迹试验(LIA)抗核抗体谱(ANAs)12项检测特异性抗体,胶体金法测定抗CCP抗体,并对结果进行相关分析。结果 (1)在433例风湿性疾病患者血清标本中,ANA核型阳性共258例,其中系统性红斑狼疮阳性率为83.03%(137/165),类风湿关节炎(RA)阳性率为26.85%(40/149),原发性干燥综合征阳性率为64.15%(34/53),混合结缔组织病阳性率为100.00%(20/20),多肌炎/皮肌炎阳性率为33.33%(8/24),进行性系统性硬化症阳性率为86.36%(19/22);健康对照组阳性率为0.00%。(2)抗双链DNA(ds-DNA)抗体、抗史密斯(Sm)抗体、抗核糖体P蛋白抗体(ARPA)、抗组蛋白抗体和核小体抗体阳性标本中均质型所占比例最高;抗尿嘧啶-1低相对分子质量核糖核蛋白(抗U1-nRNP)抗体、抗干燥综合征抗原A(SS-A)抗体、抗SS-B抗体阳性标本中,斑点型所占比例最高;抗硬皮病-70(Scl-70)抗体主要见于均质核仁混合型;抗组氨酰-tRNA合成酶(Jo-1)抗体阳性标本中,胞浆型所占比例最高;抗着丝点B(CENP B)抗体则全为着丝点阳性;(3)在175例IIFA-ANA阴性(IIFA-ANA-)标本中,LIA-ANAs阳性(LIA-ANAs+)1例;(4)433例风湿性疾病患者中,抗CCP抗体阳性82例,其中RA组阳性率为51.68%(77/149),非RA组阳性率为1.76%(5/284)。结论 ANAs中抗ds-DNA抗体、抗Jo-1抗体、抗CENP B抗体与ANA的荧光模式和风湿性疾病类型有一定关联;ANA核型以斑点型所占比例最高;IIFA-ANA-者检出LIA-ANAs+的可能性较小;抗CCP抗体对RA的诊断具有较好的灵敏度和特异性,是诊断RA的特异性血清学标志。 Objective To explore the sensitivity and correlation of the antinuclear antibodies(ANA) and anti-cyclic cit- rullinated peptide(anti-CCP) antibody in rheumatic diseases. Methods Serums of 60 health-examined individuals and 433 pa- tients with rheumatic diagnosed in the People's Hospital of Liuyang from September 2010 to February 2013 were collected. Indi- rect Immune Fluorescence Assay(IIFA) was used to detect ANA to determine the fluorescence patterns, Western blot (LIA) and the 12 items of anti-nuclear antibodies spectrum (ANAS) were adopted to detect specific antibody and the colloidal gold method was applied to detect the anti-CCP antibody. Correlation analysis was conducted on the detecting results. Results ( 1 ) In the 433 serum specimens of rheumatic diseases, the number of ANA nuclear positive was 258, thereinto the positive rate of systemic lupus erythematosus (SLE) was 83.03% (137/165);the positive rate of rheumatoid arthritis (RA) was 26.85% (40/149);the positive rate of primary sicca syndrome (PSS) was 64.15% (34/53) ;the positive rate of mixed connective tissue disease (MCTD) was 100% (20/ 20 ) ; the positive rate of polymyositis/dermatomyositis (PM/DM) was 33.33% (8/24) ; the positive rate of progressive aystemic scle- rosis (PSS) was 86.36% (19/22). While the positive rate in normal control group was 0.00%. (2) The positive specimens of dou- ble-stranded DNA (ds-DNA) antibody, anti-Sm antibody, antiribosomal P protein antibody (ARPA), anti-histone antibody and the nucleosome antibody had the highest proportion of homogeneous pattern;the positive specimens of anti-uracil-1 low molecular weight ribonucleoprotein (U 1-nRNP) antibody, anti-SS-A antibody and anti-SS-B antibody had the highest proportion of speckled pattern ; anti-scleroderma-70 (SCL-70) antibody was mainly seen in the homogeneous nucleolar mixed pattern; the positive speci- mens of anti-Jo-1 antibody had the highest proportion of cytoplasmic pattern ;anti-CENP B antibodies were all centromere positive. (3) In 175 specimens of negative IIFA-ANA (IIFA-A NA-), Only 1 cases was positive LIA-A NAs ( LIA-A NAs~). (4) In 433 patients with rheumatic diseases, 82 cases was with positive anti-CCP antibody, therein, the positive rate of RA group was 51.68% (77/ 149), and the positive rate of non-RA group was 1.76 % (5/284). Conclusion In the ANA antibodies spectral, the anti-ds-DNA antibody,anti-Jo-1 antibody,anti-CENP B antibody,and ANA fluorescence mode have some relevance to the type of rheumatic diseases. The highest proportion of the ANA nuclear types is speckled pattern. It is less likely to detect LIA-ANAs- from the pa- tients with IIFA-ANA-. Anti-CCP-antibody has good sensitivity and specificity of diagnosis of RA, and it is the specific serological mark for diagnosis of RA.
出处 《现代医药卫生》 2013年第23期3553-3555,共3页 Journal of Modern Medicine & Health
关键词 风湿性疾病 抗体 抗核 环CMP 自身抗体 自身免疫疾病 肽类 关节炎 类风湿 抗核抗体谱 抗环瓜氨酸肽抗体 Rheumatic diseases Antibodies,antinuclear Cyclic CMP Autoantibodies Autoimmune diseases Peptides,cyclic Arthritis,rheurmatoid Anti-unclear antibody spectrum Anti-cyclic citrullinated peptide antibody
  • 相关文献

参考文献12

  • 1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 2王茜,潘海峰,李文先,叶冬青.IgG型抗dsDNA抗体及其亚型与狼疮肾炎临床和病理关系探讨[J].中华疾病控制杂志,2008,12(5):420-424. 被引量:9
  • 3瞿新.红斑狼疮患者ANA、抗ds-DNA和抗ENA多肽抗体的血清学检测[J].现代预防医学,2010,37(21):4192-4193. 被引量:2
  • 4吴丽娜,郭萍,丁宁.抗核抗体荧光核型与特异性抗体相关性分析[J].免疫学杂志,2010,26(11):973-976. 被引量:9
  • 5Rantap-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies ag- ainst cyclic citrullinated peptide and IgA rheumatoid factor pre- dict the development of rheumatoid arthritis[J]. Arthritis Rheum, 2003,48 (10) : 2741-2749.
  • 6赵义,李小霞,李林,李晶,李春,栗占国.抗环瓜氨酸肽抗体与系统性红斑狼疮关节炎的相关性研究[J].中华风湿病学杂志,2009,13(2):79-83. 被引量:9
  • 7Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class I1 alleles in systemic lupus erythematosus [J]. J Rheumatol, 2008, 35 ( 1 ) : 77-83.
  • 8Ryu HJ,Takeuchi F,Kuwata S,et al. The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rlumatoid arthritis[J]. Rheu- matol Int,2011,31 (3) :315-319.
  • 9Qing YF,Zhang QB ,Zhou JG,et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic luous ervthematosus[J]. Luous,2009,18 (8) :713-717.
  • 10Barcelos F, Abreu I, Patto JV, et al Anti-cyclic citrullinated pep- tide antibodies and rheumatoid factor in Sjogren's syndrome[J]. Acta Reumatol Port, 2009,34 (4) : 608-612.

二级参考文献45

  • 1王兰兰.自身抗体检测的应用与质量保障原则[J].中华检验医学杂志,2005,28(10):987-990. 被引量:43
  • 2李永哲.自身抗体检测技术临床推广应用和质量保证工作中应重视的问题[J].中华检验医学杂志,2006,29(9):769-773. 被引量:81
  • 3杨春兰,沈荣春,徐云,鞠少卿,王惠民.系统性红斑狼疮患者血清IL-6水平与抗ENA多肽抗体谱的关系[J].现代检验医学杂志,2007,22(2):120-121. 被引量:2
  • 4Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis, 1987, d-6: 853-858.
  • 5Fischman AS, Abeles M, Zanetti M, et al. The coexistence of rheumatoid arthritis and systemic lupus erythematosus: a case report and review of the literature. J Rheumatol, 1981, 8: 405-415.
  • 6Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum, 2000, 43: 1831-1835.
  • 7Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity, 2004. 37: 495-501.
  • 8Hoffman IE, Peene I, Cebecauer L, et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis, 2005, 64: 330-332.
  • 9Martinez JB, Valero JS, Bautista AJ, et al. Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin Exp Rheumatol, 2007, 25: 47-53.
  • 10Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class Ⅱ alleles in systemic lupus erythematosus. J Rheumatol, 2008, 35: 77-83.

共引文献2810

同被引文献33

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部